866-997-4948 (US-Canada Toll Free)

Type 2 Diabetes - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : 2014-02-28

Category :

Diabetes

No. of Pages : 1052

Product Synopsis

Global Markets Direct’s, ‘Type 2 Diabetes - Pipeline Review, H1 2014’, provides an overview of the Type 2 Diabetes’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Content

Introduction
Type 2 Diabetes Overview
Therapeutics Development
Type 2 Diabetes - Therapeutics under Development by Companies
Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes
Type 2 Diabetes - Pipeline Products Glance
Type 2 Diabetes - Products under Development by Companies
Type 2 Diabetes - Products under Investigation by Universities/Institutes
Type 2 Diabetes - Companies Involved in Therapeutics Development
Type 2 Diabetes - Therapeutics Assessment
Drug Profiles
Type 2 Diabetes - Recent Pipeline Updates
Type 2 Diabetes - Dormant Projects
Type 2 Diabetes - Discontinued Products
Type 2 Diabetes - Product Development Milestones

Appendix

List of Tables


Number of Products under Development for Type 2 Diabetes, H1 2014
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Development by Companies, H1 2014 (Contd..3)
Number of Products under Development by Companies, H1 2014 (Contd..4)
Number of Products under Development by Companies, H1 2014 (Contd..5)
Number of Products under Development by Companies, H1 2014 (Contd..6)
Number of Products under Development by Companies, H1 2014 (Contd..7)
Number of Products under Development by Companies, H1 2014 (Contd..8)
Number of Products under Development by Companies, H1 2014 (Contd..9)
Number of Products under Development by Companies, H1 2014 (Contd..10)
Number of Products under Development by Companies, H1 2014 (Contd..11)
Number of Products under Development by Companies, H1 2014 (Contd..12)
Number of Products under Development by Companies, H1 2014 (Contd..13)
Number of Products under Investigation by Universities/Institutes, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Development by Companies, H1 2014 (Contd..2)
Products under Development by Companies, H1 2014 (Contd..3)
Products under Development by Companies, H1 2014 (Contd..4)
Products under Development by Companies, H1 2014 (Contd..5)
Products under Development by Companies, H1 2014 (Contd..6)
Products under Development by Companies, H1 2014 (Contd..7)
Products under Development by Companies, H1 2014 (Contd..8)
Products under Development by Companies, H1 2014 (Contd..9)
Products under Development by Companies, H1 2014 (Contd..10)
Products under Development by Companies, H1 2014 (Contd..11)
Products under Development by Companies, H1 2014 (Contd..12)
Products under Development by Companies, H1 2014 (Contd..13)
Products under Development by Companies, H1 2014 (Contd..14)
Products under Development by Companies, H1 2014 (Contd..15)
Products under Development by Companies, H1 2014 (Contd..16)
Products under Development by Companies, H1 2014 (Contd..17)
Products under Development by Companies, H1 2014 (Contd..18)
Products under Development by Companies, H1 2014 (Contd..19)
Products under Development by Companies, H1 2014 (Contd..20)
Products under Development by Companies, H1 2014 (Contd..21)
Products under Development by Companies, H1 2014 (Contd..22)
Products under Development by Companies, H1 2014 (Contd..23)
Products under Development by Companies, H1 2014 (Contd..24)
Products under Development by Companies, H1 2014 (Contd..25)
Products under Development by Companies, H1 2014 (Contd..26)
Products under Development by Companies, H1 2014 (Contd..27)
Products under Investigation by Universities/Institutes, H1 2014
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1)
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2014
Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2014
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2014
Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014
Type 2 Diabetes - Pipeline by Shionogi & Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Amgen Inc., H1 2014
Type 2 Diabetes - Pipeline by Sanofi, H1 2014
Type 2 Diabetes - Pipeline by AstraZeneca PLC, H1 2014
Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2014
Type 2 Diabetes - Pipeline by GlaxoSmithKline plc, H1 2014
Type 2 Diabetes - Pipeline by MedImmune, LLC, H1 2014
Type 2 Diabetes - Pipeline by Isis Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Gilead Sciences, Inc., H1 2014
Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H1 2014
Type 2 Diabetes - Pipeline by Merck & Co., Inc., H1 2014
Type 2 Diabetes - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Euroscreen S.A., H1 2014
Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H1 2014
Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H1 2014
Type 2 Diabetes - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014
Type 2 Diabetes - Pipeline by FibroGen, Inc., H1 2014
Type 2 Diabetes - Pipeline by Ipsen S.A., H1 2014
Type 2 Diabetes - Pipeline by Piramal Enterprises Limited, H1 2014
Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H1 2014
Type 2 Diabetes - Pipeline by Teijin Pharma Limited, H1 2014
Type 2 Diabetes - Pipeline by Novartis AG, H1 2014
Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H1 2014
Type 2 Diabetes - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Forest Laboratories, Inc., H1 2014
Type 2 Diabetes - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014
Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H1 2014
Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Les Laboratoires Servier SAS, H1 2014
Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014
Type 2 Diabetes - Pipeline by Pfizer Inc., H1 2014
Type 2 Diabetes - Pipeline by Ranbaxy Laboratories Limited, H1 2014
Type 2 Diabetes - Pipeline by Zydus Cadila Healthcare Limited, H1 2014
Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2014
Type 2 Diabetes - Pipeline by Biodel Inc., H1 2014
Type 2 Diabetes - Pipeline by Bayer AG, H1 2014
Type 2 Diabetes - Pipeline by OPKO Health, Inc., H1 2014
Type 2 Diabetes - Pipeline by MannKind Corporation, H1 2014
Type 2 Diabetes - Pipeline by Halozyme Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Toray Industries, Inc., H1 2014
Type 2 Diabetes - Pipeline by Merck KGaA, H1 2014
Type 2 Diabetes - Pipeline by Alchemia Limited, H1 2014
Type 2 Diabetes - Pipeline by Addex Therapeutics, H1 2014
Type 2 Diabetes - Pipeline by Evotec AG, H1 2014
Type 2 Diabetes - Pipeline by AlbireoPharma, H1 2014
Type 2 Diabetes - Pipeline by GW Pharmaceuticals plc, H1 2014
Type 2 Diabetes - Pipeline by Harbor Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H1 2014
Type 2 Diabetes - Pipeline by Genfit SA, H1 2014
Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Mesoblast Limited, H1 2014
Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014
Type 2 Diabetes - Pipeline by ConjuChem Biotechnologies Inc., H1 2014
Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Arena Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H1 2014
Type 2 Diabetes - Pipeline by CSL Limited, H1 2014
Type 2 Diabetes - Pipeline by ProteoTech, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Yuhan Corporation, H1 2014
Type 2 Diabetes - Pipeline by XOMA Corporation, H1 2014
Type 2 Diabetes - Pipeline by Immuron Limited, H1 2014
Type 2 Diabetes - Pipeline by IPCA Laboratories Limited, H1 2014
Type 2 Diabetes - Pipeline by Xenetic Biosciences plc, H1 2014
Type 2 Diabetes - Pipeline by Handok Inc., H1 2014
Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by LG Life Sciences, Ltd., H1 2014
Type 2 Diabetes - Pipeline by Transition Therapeutics Inc., H1 2014
Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Uni-Bio Science Group Ltd., H1 2014
Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H1 2014
Type 2 Diabetes - Pipeline by Summit Corporation plc, H1 2014
Type 2 Diabetes - Pipeline by Phynova Group Ltd, H1 2014
Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H1 2014
Type 2 Diabetes - Pipeline by DiaMedica Inc., H1 2014
Type 2 Diabetes - Pipeline by NeuroVive Pharmaceutical AB, H1 2014
Type 2 Diabetes - Pipeline by Angelini Group, H1 2014
Type 2 Diabetes - Pipeline by Debiopharm International S.A., H1 2014
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd., H1 2014
Type 2 Diabetes - Pipeline by CJ CheilJedang Corp., H1 2014
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2014
Type 2 Diabetes - Pipeline by Aurigene Discovery Technologies Limited, H1 2014
Type 2 Diabetes - Pipeline by ActogeniX NV, H1 2014
Type 2 Diabetes - Pipeline by Camurus AB, H1 2014
Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H1 2014
Type 2 Diabetes - Pipeline by reMYND, H1 2014
Type 2 Diabetes - Pipeline by Wellstat Therapeutics Corporation, H1 2014
Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H1 2014
Type 2 Diabetes - Pipeline by Cortendo Invest AB, H1 2014
Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Protemix Corporation Limited, H1 2014
Type 2 Diabetes - Pipeline by Allozyne, Inc., H1 2014
Type 2 Diabetes - Pipeline by Metabolic Solutions Development Co., H1 2014
Type 2 Diabetes - Pipeline by Zafgen Inc., H1 2014
Type 2 Diabetes - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Melior Discovery, Inc., H1 2014
Type 2 Diabetes - Pipeline by Diabetology Limited, H1 2014
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2014
Type 2 Diabetes - Pipeline by Zealand Pharma A/S, H1 2014
Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Theracos, Inc., H1 2014
Type 2 Diabetes - Pipeline by Versartis, Inc., H1 2014
Type 2 Diabetes - Pipeline by Kainos Medicine, Inc., H1 2014
Type 2 Diabetes - Pipeline by Nordic Bioscience a/s, H1 2014
Type 2 Diabetes - Pipeline by InteKrin Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Virobay Inc., H1 2014
Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H1 2014
Type 2 Diabetes - Pipeline by Avaxia Biologics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Omeros Corporation, H1 2014
Type 2 Diabetes - Pipeline by TransTech Pharma, Inc., H1 2014
Type 2 Diabetes - Pipeline by Bridge Bioresearch Plc, H1 2014
Type 2 Diabetes - Pipeline by Synthetic Biologics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Targacept, Inc., H1 2014
Type 2 Diabetes - Pipeline by N-Gene Research Laboratories, Inc., H1 2014
Type 2 Diabetes - Pipeline by Obio Pharmaceutical Holdings Limited, H1 2014
Type 2 Diabetes - Pipeline by ChemoCentryx, Inc., H1 2014
Type 2 Diabetes - Pipeline by USV Limited, H1 2014
Type 2 Diabetes - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by CureDM, Inc., H1 2014
Type 2 Diabetes - Pipeline by Verva Pharmaceuticals Limited, H1 2014
Type 2 Diabetes - Pipeline by Exsulin Corporation, H1 2014
Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H1 2014
Type 2 Diabetes - Pipeline by NasVax Ltd., H1 2014
Type 2 Diabetes - Pipeline by Stelic Institute & Co., H1 2014
Type 2 Diabetes - Pipeline by Vybion, Inc., H1 2014
Type 2 Diabetes - Pipeline by Regulus Therapeutics Inc., H1 2014
Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2014
Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2014
Type 2 Diabetes - Pipeline by Ardelyx, Inc., H1 2014
Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd., H1 2014
Type 2 Diabetes - Pipeline by Mitsubishi Pharmaceutical Corporation, H1 2014
Type 2 Diabetes - Pipeline by Receptos, Inc., H1 2014
Type 2 Diabetes - Pipeline by MicroDose Therapeutx, Inc., H1 2014
Type 2 Diabetes - Pipeline by Sirona Biochem Corp, H1 2014
Type 2 Diabetes - Pipeline by XBiotech USA, Inc., H1 2014
Type 2 Diabetes - Pipeline by Carmot Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2014
Type 2 Diabetes - Pipeline by Serometrix, LLC, H1 2014
Type 2 Diabetes - Pipeline by PharmaIN Corporation, H1 2014
Type 2 Diabetes - Pipeline by Stempeutics Research Private Limited, H1 2014
Type 2 Diabetes - Pipeline by Serodus ASA, H1 2014
Type 2 Diabetes - Pipeline by SignPath Pharma Inc, H1 2014
Type 2 Diabetes - Pipeline by Elcelyx Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Thermalin Diabetes Inc., H1 2014
Type 2 Diabetes - Pipeline by Selvita S.A, H1 2014
Type 2 Diabetes - Pipeline by Poxel SA, H1 2014
Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H1 2014
Type 2 Diabetes - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014
Type 2 Diabetes - Pipeline by Neopharm Co., Ltd., H1 2014
Type 2 Diabetes - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014
Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014
Type 2 Diabetes - Pipeline by Metabolys S.A.S., H1 2014
Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Cardiolynx AG, H1 2014
Type 2 Diabetes - Pipeline by TWi Pharmaceuticals, Inc., H1 2014
Type 2 Diabetes - Pipeline by Allinky Biopharma, H1 2014
Type 2 Diabetes - Pipeline by Rhizen Pharmaceuticals SA, H1 2014
Type 2 Diabetes - Pipeline by Hua Medicine Ltd., H1 2014
Type 2 Diabetes - Pipeline by Curaxys, S.L., H1 2014
Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H1 2014
Type 2 Diabetes - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014
Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2014
Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H1 2014
Type 2 Diabetes - Pipeline by Biospherics.net Incorporated, H1 2014
Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Type 2 Diabetes Therapeutics - Recent Pipeline Updates, H1 2014
Type 2 Diabetes - Dormant Projects, H1 2014
Type 2 Diabetes - Discontinued Products, H1 2014

List of Figures


Number of Products under Development for Type 2 Diabetes, H1 2014
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Assessment by Combination Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Greece: market of non-domestic equipment for coking or heating food

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the non-domestic equipment for coking or heating food market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the non-domestic equipment for coking or heating food market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development...

  • Poland: market of sacks and bags of polymers

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the sacks and bags of polymers market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the sacks and bags of polymers market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents...

  • Superconductors Market - Global industry Analysis, Market Share, Size, Growth, and Forecast, 2012 - 2018

    By - Transparency

    A superconductor is a material that transfers electrons at critical temperature (Tc) from one atom to another without generating any resistance (heat, sound, or any other form of energy). The demand for superconductors is growing rapidly due to their increasing applications in commercial, health care, and industrial sectors. Superconductors are also widely used in technologically advanced studies and in magnetic resonance imaging.  Asia-Pacific is the leading regional market for this industry and is expected to dominate in the future with the expected positive economic...